Breast

GS-US-595-6184 at https://clinicaltrials.gov/study/NCT05633654

A randomized, open-label, phase 3 study of adjuvant sacituzumab govitecan (Trodelvy®) and pembrolizumab (Keytruda®) vs. treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy

Cancer Type: Breast triple negative

Principal Investigator: Dr. Debra Brandt

Please contact Clinical Trials Office for more details: 561-263-5791

NRG – BR009 at https://clinicaltrials.gov/study/NCT05879926?term=NCT05879926&rank=1

NCT05879926

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to ovarian Function Suppression plus Endocrine therapy in Premenopausal Patients with pN0-, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤25 (OFSET)

Cancer Type: Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25

Principal Investigator: Dr. Debra Brandt

Please contact Clinical Trials Office for more details: 561-263-5791

NRG – S2212 at https://clinicaltrials.gov/study/NCT05929768

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer, a Randomized Phase III Study

Cancer Type: Triple Negative Breast Cancer

Principal Investigator: Dr. Debra Brandt

Please contact Clinical Trials Office for more details: 561-263-5791

NRG – S2206 at Study Details | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | ClinicalTrials.gov

Ph 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy vrs Chemotherapy Alone for Adults w/MammPrint Ultrahigh (MP2) HR + HER2- Stage II-III BC

Principal Investigator: Dr. Debra Brandt

Please contact Clinical Trials Office for more details: 561-263-5791